Join us in-person in Utrecht, Netherlands for the SPS Annual Meeting 2025.
Poster presentation
Ion channel trafficking studies using automated patch clamp technology
Throughout the drug development process, one of the most common adverse effects leading to drug failure is cardiac arrhythmia. This condition arises from dysfunctions in the activity or expression of various ion channels that shape the cardiac action potential. Moreover, ion channel trafficking is a contributing factor in both inherited and acquired arrhythmias. Unlike the rapid effects of acute ion channel inhibition, disruptions in trafficking typically emerge over longer periods, ranging from several hours to days.
Several pharmacological agents, such as arsenic trioxide and pentamidine, can induce hERG channel deficiency by interfering with its biogenesis and intracellular trafficking.
Presented by Laura Castelletti, Manager • Compound Profiling & Safety Assessment
